MedSurg Performance Summary Measure Q4 2022 Q4 2021 Change Y/Y ($ in millions) Reported Net Sales $1,297M $1,243M +4.4% Operating Income* % 33.7% 32.6% +100 bps * Represents operating income as a percentage of operational net sales, both excluding the impact of foreign currency, which is a non-GAAP measure. Q4 + FY 2022 Highlights • Endoscopy: Q4:22 Global net sales +2.4% as reported, +7.4% operational*/organic*; FY:22 Global net sales +3.7% as reported, +8.1% operational*/organic* ◦ Strong global success supported by innovative products, AXIOS™ and Single-Use-Imaging, both growing over 20% in 2022. ◦ Announced agreement to acquire Apollo Endosurgery, which adds a complementary and innovative endoluminal surgery portfolio; we expect to close this transaction as well as our majority stake investment in MI Tech in 1H:23. • Urology: Q4:22 Global net sales +8.2% as reported, +11.8% operational*/organic*; FY:22 Global net sales +12.0% as reported, +14.9% operational*, +9.7% organic* ◦ Double digit growth across all franchises in Q4 fueled by new and ongoing product launches and continued global expansion. ◦ Full year performance driven by global strength of key products such as LithoVue™, Rezūm™, and SpaceOAR™ as well as the acquisition of Lumenis and the Moses Laser technology. • Neuromodulation: Q4:22 Global net sales +2.1% as reported, +4.9% operational*/organic*; FY:22 Global net sales +0.9% as reported, +3.5% operational*/organic* ◦ Q4 global SCS growth of 4%, with differentiated offerings, including Wavewriter Alpha™, FAST, and our Cognita practice optimization suite of tools. ◦ The Brain franchise grew double digits in Q4 and low-double digits in FY:22, with continued momentum from 2022 new product launches and the recent launch of the Vercise™ 2 in 1 lead extension. 5 Q4 2022 Financial & Operational Highlights | February 1, 2023